EDIT
Price
$1.86Alerts
Change
-$0.30 (-13.82%)
Updated
Nov 16, 04:59 PM (EDT)
Capitalization
394.7M
101 days until earnings call
Intraday BUY SELL Signals
PRTA
Price
$7.96Alerts
Change
-$0.21 (-2.57%)
Updated
Nov 16, 01:58 PM (EDT)
Capitalization
409.16M
101 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EDIT vs PRTA

EDIT vs PRTA Comparison Chart in %
View a ticker or compare two or three
A.I.Advisor
Oct 21, 2026

Which Stock Would AI Choose? Editas Medicine (EDIT) vs. Prothena (PRTA) Stock Comparison

Key Takeaways

  • EDIT is a clinical-stage CRISPR gene-editing company rebuilding its pipeline around the in vivo candidate EDIT-401, while PRTA is a late-stage neuroscience and amyloid-focused biotech heavily reliant on partnered programs.
  • EDIT has shown stronger year-to-date momentum, whereas PRTA has lagged in 2026 despite a more established clinical portfolio.
  • PRTA holds a larger cash balance and a debt-free balance sheet, while EDIT carries higher volatility (beta) and a more concentrated, earlier-stage pipeline.
  • Both names carry elevated short interest as a percentage of float, reflecting meaningful investor skepticism around each company's catalysts.
  • Risk profiles differ sharply: EDIT hinges on first-in-human gene-editing data, while PRTA depends on milestones and readouts controlled by its large pharmaceutical partners.

Introduction

Investors evaluating clinical-stage biotechnology often weigh two very different models: a high-conviction platform play betting on a single transformative technology versus a diversified, partner-funded pipeline spread across several disease areas. That contrast defines this stock comparison between Editas Medicine (EDIT), a pioneer in CRISPR gene editing, and Prothena Corporation (PRTA), a protein-dysregulation specialist focused on neurodegenerative and amyloid diseases. Both companies are pre-revenue on a product basis, trade at sub-billion-dollar market capitalizations, and carry substantial binary event risk. Growth-oriented traders tracking momentum and relative performance may find EDIT appealing, while investors prioritizing balance-sheet stability and diversified catalysts may favor PRTA.

EDIT Overview and Recent Performance

Editas Medicine (EDIT) develops medicines based on CRISPR (clustered regularly interspaced short palindromic repeats) gene-editing technology. After discontinuing its reni-cel sickle cell program in late 2024 and reducing its workforce by roughly 65%, the company pivoted to an in vivo strategy centered on EDIT-401, an experimental one-time therapy designed to lower LDL-C (low-density lipoprotein cholesterol) by upregulating the LDL receptor gene in patients with HeFH (heterozygous familial hypercholesterolemia, an inherited cause of high cholesterol).

In recent weeks, EDIT secured regulatory clearance in Australia to begin a first-in-human Phase 1/2 trial of EDIT-401, a milestone that has helped sustain investor interest. Preclinical data reported earlier in 2026 showed mean LDL-C reductions of roughly 90% in non-human primates. The company reported a second-quarter 2026 loss of $0.15 per share on about $11.9 million in collaboration revenue and held approximately $211.6 million in cash as of mid-2026. Shares have outperformed the broader market so far this year, though the stock remains well below its 52-week high and carries a beta above 2, indicating above-average volatility.

PRTA Overview and Recent Performance

Prothena Corporation (PRTA) is a late-stage clinical biotechnology company built around protein dysregulation, targeting conditions such as Parkinson's disease, Alzheimer's disease, ALS (amyotrophic lateral sclerosis), and ATTR-CM (transthyretin amyloidosis with cardiomyopathy). Much of its value rests on partnered assets: prasinezumab with Roche, coramitug with Novo Nordisk, and moponetug and PRX019 with Bristol Myers Squibb.

Recent market activity has been mixed. A $50 million milestone payment from Novo Nordisk drove a profitable first quarter of 2026, but second-quarter revenue fell back sharply as milestone income was non-recurring, and PRTA returned to a net loss. The company ended the second quarter with roughly $289 million in cash and no debt, and management reduced its projected net cash burn for 2026. Despite a stable financial position, the stock has declined on a year-to-date and three-month basis, with sentiment weighed down by the timing of external, partner-controlled catalysts that are not expected to produce pivotal readouts until later this decade.

Trending AI Robots

For investors who prefer a systematic approach to evaluating names like these, Tickeron's Trending AI Robots page offers a curated view of its AI trading bots. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, each operating with its own trading style, strategy, timeframe, performance record, and watchlist. Only the most suitable bots for current market conditions earn a place in the Trending AI Robots section, helping traders cut through the noise of a crowded automated-trading landscape. Whether you are monitoring momentum in EDIT or stability in PRTA, reviewing these curated bots can add a data-driven layer to your own analysis.

Head-to-Head Comparison

The two companies occupy different positions within biotechnology. EDIT is a concentrated platform story: its entire near-term thesis depends on EDIT-401 successfully advancing through early clinical testing, which creates high upside potential alongside high single-program risk. PRTA, by contrast, spreads risk across several partnered programs, but cedes much of its catalyst control to Roche, Novo Nordisk, and Bristol Myers Squibb.

On relative performance, EDIT has displayed stronger recent momentum, rising substantially in 2026, while PRTA has trended lower over the same period despite positive one-year performance. On stability, PRTA benefits from a larger cash position, no debt, and lower beta, whereas EDIT faces higher volatility and a tighter runway-to-catalyst profile. Both stocks show comparable elevated short interest as a percentage of float, indicating active debate over their outlooks. Sector exposure is also distinct: EDIT is tied to the emerging gene-editing field, while PRTA sits within the more established antibody and neurodegenerative space.

Tickeron AI Verdict

Based on observable factors such as trend consistency, catalyst proximity, and relative positioning, Tickeron's AI would likely favor EDIT in the current environment. Its stronger recent momentum, combined with a near-term clinical milestone from the Australian trial clearance, aligns more closely with trend-following signals. That said, PRTA presents a more stable balance sheet and a diversified catalyst calendar, which may appeal to models that weight volatility and downside protection more heavily. The verdict is therefore probabilistic rather than definitive: EDIT currently exhibits the more favorable momentum profile, while PRTA offers comparatively greater financial resilience.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

VS
EDIT vs. PRTA commentary
Nov 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and PRTA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for EDIT with price predictions
Nov 13, 2026

EDIT sees MACD Histogram crosses below signal line

EDIT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 11, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 49 instances where the indicator turned negative. In 46 of the 49 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 75 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

EDIT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.

The 50-day moving average for EDIT moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +7.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 182 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 125 of 154 cases where EDIT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.749) is normal, around the industry mean (3.498). P/E Ratio (-3.894) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for PRTA with price predictions
Nov 13, 2026

PRTA in downward trend: price expected to drop as it breaks its higher Bollinger Band on October 28, 2026

PRTA broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 35 similar instances where the stock broke above the upper band. In 31 of the 35 cases the stock fell afterwards. This puts the odds of success at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PRTA as a result. In 81 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

The Moving Average Convergence Divergence Histogram (MACD) for PRTA turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 40 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.

PRTA moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for PRTA entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 75 cases where PRTA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

Following a +11.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRTA advanced for three days, in 202 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.426) is normal, around the industry mean (3.498). P/E Ratio (-9.840) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (8.104) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. PRTA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
EDIT vs PRTA: Fundamental Ratings
EDIT
PRTA
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
15
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9994
PRICE GROWTH RATING
1..100
7270
P/E GROWTH RATING
1..100
3034
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRTA's Valuation (15) in the Biotechnology industry is somewhat better than the same rating for EDIT (53). This means that PRTA’s stock grew somewhat faster than EDIT’s over the last 12 months.

PRTA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that PRTA’s stock grew similarly to EDIT’s over the last 12 months.

PRTA's SMR Rating (94) in the Biotechnology industry is in the same range as EDIT (99). This means that PRTA’s stock grew similarly to EDIT’s over the last 12 months.

PRTA's Price Growth Rating (70) in the Biotechnology industry is in the same range as EDIT (72). This means that PRTA’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's P/E Growth Rating (30) in the Biotechnology industry is in the same range as PRTA (34). This means that EDIT’s stock grew similarly to PRTA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITPRTA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
77%
Momentum
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
87%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
87%
Advances
ODDS (%)
Bullish Trend 8 days ago
80%
Bullish Trend 8 days ago
75%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 4 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
76%
Bearish Trend 4 days ago
89%
Aroon
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
85%
COMPARISON
Comparison
Nov 16, 2026
Stock price -- (EDIT: $2.17 vs. PRTA: $8.16)
Brand notoriety: EDIT and PRTA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 107% vs. PRTA: 53%
Market capitalization -- EDIT: $394.7M vs. PRTA: $409.16M
EDIT [@Biotechnology] is valued at $394.7M. PRTA’s [@Biotechnology] market capitalization is $409.16M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 1 FA rating(s) are green while PRTA’s FA Score has 1 green FA rating(s).

  • EDIT’s FA Score: 1 green, 4 red.
  • PRTA’s FA Score: 1 green, 4 red.
According to our system of comparison, PRTA is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 4 TA indicator(s) are bullish while PRTA’s TA Score has 2 bullish TA indicator(s).

  • EDIT’s TA Score: 4 bullish, 5 bearish.
  • PRTA’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, EDIT is a better buy in the short-term than PRTA.

Price Growth

EDIT (@Biotechnology) experienced а -15.56% price change this week, while PRTA (@Biotechnology) price change was +2.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.

Reported Earning Dates

EDIT is expected to report earnings on Feb 25, 2027.

PRTA is expected to report earnings on Feb 25, 2027.

Industries' Descriptions

@Biotechnology (-3.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

PRTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRTA has been loosely correlated with MGTX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if PRTA jumps, then MGTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRTA
1D Price
Change %
PRTA100%
-0.85%
MGTX - PRTA
47%
Loosely correlated
+4.44%
EDIT - PRTA
47%
Loosely correlated
+1.40%
CRSP - PRTA
44%
Loosely correlated
-0.89%
ARVN - PRTA
44%
Loosely correlated
-0.73%
VYGR - PRTA
43%
Loosely correlated
+1.76%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BOND.X0.0115080.002628
+29.59%
BarnBridge cryptocurrency
QNT.X156.78032013.548920
+9.46%
Quant cryptocurrency
FTT.X0.2051850.011240
+5.80%
FTX Token cryptocurrency
FLUX.X0.0476940.002173
+4.77%
Flux cryptocurrency
WRX.X0.016320-0.000320
-1.92%
WazirX cryptocurrency